A Phase 1 interventional study of BI 1265162 and Placebo in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-11.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this trial is to investigate the safety and tolerability of BI 1265162 in healthy male subjects following inhalative administration of single rising doses.
Secondary objective is the exploration of the pharmacokinetics (PK) of BI 1265162 after single dosing.
To investigate safety, tolerability and pharmacokinetics of BI 1265162 in man.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BI 1265162
Drug: BI 1265162
Placebo
Drug: Placebo
Single rising dose groups
Single rising dose groups
Percentage of Participants With Drug-related Adverse Events (AEs)
Percentage of participants with drug-related adverse events (AEs).
Time frame: From drug administration until end of trial examination, up to 9 days
Maximum Measured Concentration of BI 1265162 in Plasma (Cmax)
Maximum measured concentration of BI 1265162 in plasma (Cmax).
Time frame: Pharmacokinetic samples were taken pre-dose and 0:02 (hour: minute), 0:05, 0:10, 0:15, 0:20 , 0:30, 0:45, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 48:00 and 72:00 (Last time point only taken for 1200 µg) after drug administration
Area Under the Concentration-time Curve of the BI 1265162 in Plasma Over the Time Interval 0 to 1 Hour Post-dose (AUC0-1)
Area under the concentration-time curve of the BI 1265162 in plasma over the time interval 0 to 1 hour post-dose (AUC0-1)
Time frame: Pharmacokinetic samples were taken pre-dose and 0:02 (hour: minute), 0:05, 0:10, 0:15, 0:20 , 0:30, 0:45, 1:00 after drug administration
This was single-blind, partially randomised, and placebo controlled within parallel dose groups trial. A total of 57 participants were entered and 56 were treated. The dose range for Treatment A to Treatment G was 3 μg to 1200 μg.
| Milestone | 3 Microgram BI 1265162 | 10 Microgram BI 1265162 | 30 Microgram BI 1265162 | 100 Microgram BI 1265162 | 300 Microgram BI 1265162 | 600 Microgram BI 1265162 | 1200 Microgram BI 1265162 | Placebo Matching BI 1265162 |
|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 14 |
| Completed | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 14 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Percentage of participants with drug-related adverse events (AEs).
| Percentage of participants (%) | 3 Microgram BI 1265162 | 10 Microgram BI 1265162 | 30 Microgram BI 1265162 | 100 Microgram BI 1265162 | 300 Microgram BI 1265162 | 600 Microgram BI 1265162 | 1200 Microgram BI 1265162 | Placebo Matching BI 1265162 |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Drug-related Adverse Events (AEs) | 0 | 0 | 0 | 16.7 | 16.7 | 0 | 0 | 0 |
Maximum measured concentration of BI 1265162 in plasma (Cmax).
| Picomoles Per Litre (pmol/L) | 3 Microgram BI 1265162 | 10 Microgram BI 1265162 | 30 Microgram BI 1265162 | 100 Microgram BI 1265162 | 300 Microgram BI 1265162 | 600 Microgram BI 1265162 | 1200 Microgram BI 1265162 |
|---|---|---|---|---|---|---|---|
| Maximum Measured Concentration of BI 1265162 in Plasma (Cmax) | 17.8 ± 32.9 | 50.1 ± 46.6 | 129.0 ± 40.1 | 462.0 ± 53.2 | 1090.0 ± 26.0 | 3130.0 ± 30.6 | 6500.0 ± 73.1 |
Area under the concentration-time curve of the BI 1265162 in plasma over the time interval 0 to 1 hour post-dose (AUC0-1)
| Picomoles*Hour Per Litre (pmol*h/L) | 3 Microgram BI 1265162 | 10 Microgram BI 1265162 | 30 Microgram BI 1265162 | 100 Microgram BI 1265162 | 300 Microgram BI 1265162 | 600 Microgram BI 1265162 | 1200 Microgram BI 1265162 |
|---|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve of the BI 1265162 in Plasma Over the Time Interval 0 to 1 Hour Post-dose (AUC0-1) | 10.4 ± 42.4 | 28.7 ± 49.0 | 73.7 ± 43.4 | 299.0 ± 45.2 | 706.0 ± 25.9 | 1700.0 ± 34.5 | 3920.0 ± 76.4 |
Collected over From drug administration until end of trial examination, up to 9 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 3 Microgram BI 1265162 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| 10 Microgram BI 1265162 | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| 30 Microgram BI 1265162 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| 100 Microgram BI 1265162 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| 300 Microgram BI 1265162 | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| 600 Microgram BI 1265162 | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| 1200 Microgram BI 1265162 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Placebo Matching BI 1265162 | 0/14 (0%) | 0/14 (0%) | 2/14 (14.3%) |
| Event | 3 Microgram BI 1265162 | 10 Microgram BI 1265162 | 30 Microgram BI 1265162 | 100 Microgram BI 1265162 | 300 Microgram BI 1265162 | 600 Microgram BI 1265162 | 1200 Microgram BI 1265162 | Placebo Matching BI 1265162 |
|---|---|---|---|---|---|---|---|---|
| Dry eyeEye disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/14 |
| NasopharyngitisInfections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 1/14 |
| HeadacheNervous system disorders | 1/6 | 0/6 | 1/6 | 0/6 | 1/6 | 0/6 | 0/6 | 1/14 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/14 |
Treated set(TS):This subject set included all subjects who had received at least 1 dose of trial medication.
| Age, Continuous(Years) | 3 Microgram BI 1265162 | 10 Microgram BI 1265162 | 30 Microgram BI 1265162 | 100 Microgram BI 1265162 | 300 Microgram BI 1265162 | 600 Microgram BI 1265162 | 1200 Microgram BI 1265162 | Placebo Matching BI 1265162 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 31.3 ± 3.6 | 31.8 ± 5.2 | 28.7 ± 4.7 | 44.7 ± 5.6 | 32.0 ± 7.3 | 34.5 ± 8.9 | 38.8 ± 9.8 | 35.1 ± 11.0 | 34.7 ± 8.8 |
| Sex: Female, Male(Participants) | 3 Microgram BI 1265162 | 10 Microgram BI 1265162 | 30 Microgram BI 1265162 | 100 Microgram BI 1265162 | 300 Microgram BI 1265162 | 600 Microgram BI 1265162 | 1200 Microgram BI 1265162 | Placebo Matching BI 1265162 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 14 | 56 |
| Ethnicity (NIH/OMB)(Participants) | 3 Microgram BI 1265162 | 10 Microgram BI 1265162 | 30 Microgram BI 1265162 | 100 Microgram BI 1265162 | 300 Microgram BI 1265162 | 600 Microgram BI 1265162 | 1200 Microgram BI 1265162 | Placebo Matching BI 1265162 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Not Hispanic or Latino | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 13 | 55 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 3 Microgram BI 1265162 | 10 Microgram BI 1265162 | 30 Microgram BI 1265162 | 100 Microgram BI 1265162 | 300 Microgram BI 1265162 | 600 Microgram BI 1265162 | 1200 Microgram BI 1265162 | Placebo Matching BI 1265162 | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| White | 6 | 6 | 6 | 6 | 6 | 6 | 5 | 14 | 55 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Nov 2017 to primary completion in Mar 2018, 3 months.
Results were first posted in Feb 2022, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BI-1265162